Datopotamab deruxtecan with durvalumab and carboplatin for previously untreated, locally advanced, unresectable non-small cell lung cancer

Datopotamab deruxtecan in combination with durvalumab and carboplatin is in clinical development for the treatment of previously untreated, locally advanced, or metastatic non-small cell lung cancer (NSCLC), without actionable genomic alterations. NSCLC is the most common lung cancer. Locally advanced cancer has grown outside the body part it started in but has not yet spread to other parts of the body. Metastatic cancer is a cancer that has spread from the part of the body where it started (the primary site) to other parts of the body. Actionable genomic alterations refer to a DNA change that, if detected in a patient's tumour, would be expected (or predicted) to affect a patient's response to treatment. NSCLC is diagnosed at an advanced stage in nearly 50% of patients and often has a poor prognosis with worsening outcomes after each line of subsequent therapy therefore additional treatment options are needed in this setting.